??? Entered into a definitive agreement with Geron Corporation in which BioTime???s subsidiary BioTime Acquisition Corporation (BAC) will acquire the patents and patent applications, biological materials, and other assets related to Geron???s human embryonic stem (hES) cell programs, including Geron???s Phase I clinical trial of oligodendrocyte progenitor cells in patients with acute spinal cord i